Glass Wealth Management Co LLC Decreases Stock Holdings in Sanofi (NASDAQ:SNY)

Glass Wealth Management Co LLC cut its holdings in Sanofi (NASDAQ:SNY) by 0.8% in the third quarter, HoldingsChannel reports. The firm owned 30,845 shares of the company’s stock after selling 260 shares during the quarter. Glass Wealth Management Co LLC’s holdings in Sanofi were worth $1,778,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. ProShare Advisors LLC raised its position in Sanofi by 7.1% during the first quarter. ProShare Advisors LLC now owns 19,197 shares of the company’s stock valued at $933,000 after purchasing an additional 1,268 shares during the period. Blair William & Co. IL purchased a new stake in Sanofi during the 1st quarter valued at $204,000. Jacobi Capital Management LLC raised its holdings in Sanofi by 10.4% during the 1st quarter. Jacobi Capital Management LLC now owns 5,503 shares of the company’s stock valued at $267,000 after buying an additional 518 shares during the period. Clearbridge Investments LLC lifted its position in Sanofi by 3.2% in the first quarter. Clearbridge Investments LLC now owns 172,214 shares of the company’s stock worth $8,370,000 after buying an additional 5,411 shares during the last quarter. Finally, Lake Street Advisors Group LLC boosted its stake in Sanofi by 24.8% during the first quarter. Lake Street Advisors Group LLC now owns 7,174 shares of the company’s stock worth $349,000 after buying an additional 1,426 shares during the period. Institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Up 0.3 %

Shares of SNY opened at $47.97 on Monday. The firm has a fifty day moving average price of $54.65 and a 200-day moving average price of $52.23. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $121.74 billion, a P/E ratio of 24.47, a P/E/G ratio of 1.22 and a beta of 0.61. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. The company had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.55 EPS. Equities research analysts expect that Sanofi will post 4.29 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.